Hemab
Shan Wang is a Senior Associate at RA Capital Management and a Hemab Board Observer. She earned a PhD in Neuroscience from Harvard Medical School, United States.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Hemab
Hemab Therapeutics ApS is an emerging biotech company supported by Novo Holdings A/S with the aim of developing novel treatments for rare and underserved bleeding disorders. Based in Copenhagen, the company is led by a team of drug developers and scientists with deep expertise in haemophilia. Hemab has exclusive licences to state-of-the-art antibody technologies from both Novo Nordisk A/S and Genmab A/S.